FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK
BioPharma DiveBioPharma Dive staffNovember 18, 2026
The FDA had several issues with ivonescimab, according to the letter. Elsewhere, Sellas shares rocketed on results for a leukemia vaccine and Biogen and Lilly struck up new R D pacts.
